Anti-Human CD33 Recombinant Antibody (Vadastuximab) (CAT#: TAB-471CQ)

Figure 1 Mean concentration-time profiles and ADC to TAb ratio.

(A) Cycle 1 arithmetic mean vadastuximab talirine ADC plasma concentration-time profiles after administration of the first dose of vadastuximab talirine at doses ranging from 5 to 60 µg/kg. (B) Cycle 1 arithmetic mean vadastuximab talirine ADC plasma concentration-time profiles after administration of the first dose of vadastuximab talirine at doses of 20 and 40 µg/kg. (C) Cycle 1 arithmetic mean vadastuximab talirine ADC plasma concentration-time profile after administration of 2 doses of vadastuximab talirine, both at 20 µg/kg. Each dose represents n = 12. (D) Ratio of ADC over TAb concentration vs time. n = x represents the total number of subjects in each cohort. NPM40, 40 µg/kg-dose level NPMI mutation cohort; PAL20, 20 µg/kg-dose level post-alloHSCT cohort; PAL40, 40-µg/kg-dose level post-alloHSCT cohort; TN40, 40-µg/kg dose level treatment-naive cohort.

Stein, E. M., Walter, R. B., Erba, H. P., Fathi, A. T., Advani, A. S., Lancet, J. E., ... & Faderl, S. (2018). A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia. Blood, 131(4), 387-396.